spacer
home > pmps > winter 2017 > thinking human
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Thinking Human

Two main challenges with human factors (HF) stand out at the moment: one is that it has become a ‘hot topic’ that people do not want to hear about anymore; the other is that it is perhaps not clear what the lasting and valuable contribution of it will be. However, it can have real benefits in the development of inhalers. It is important to look at the HF perspective and how it might contribute to future advancements in both medical devices and technology.

Innovative Inhalers


It is not helpful for HF to be possessive, or seek to claim ownership of any particular aspect of the development of inhalers or their life in the world. This perspective is just one voice among many, and countless progressions in inhalers occurred before HF were identified as an integral part of the design process. There are three aspects of the inhaler-user relationship where the industry looks to improve.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Julian Dixon is Director of HF at Team Consulting, the leading medical device development consultancy based in Cambridge, UK. He takes an active role in understanding emerging FDA expectations and practices with regard to HF, particularly as they apply to combination products. Predominantly in the respiratory and parenteral sectors, Julian has worked on a large number of drug delivery device development projects and has fulfilled a range of consultancy roles for clients including HF, facilitation, decision support and technical problem solving.
spacer
Julian Dixon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

By Your Side for a Healthier World

West Pharmaceutical Services, Inc.

Every day, injectable drugs are administered to improve the lives of millions of patients around the world. And every day, West is working by your side to design and manufacture drug packaging and delivery systems that will bring our customers’ drugs from concept to the patient more efficiently, reliably and safely. West understands our customers’ challenges and helps with solutions every step of the way, with cutting-edge production technologies, an unmatched expertise in global regulatory compliance, and an ever-growing knowledge base of pharmaceutical drug product testing, development, packaging and delivery. Whether focused on one piece of the process or an end-to-end solution, West is by your side for a healthier world.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement